Further evidence for an anti-inflammatory role of artesunate in experimental cerebral malaria

Aline S Miranda1,2*, Fátima Brant1,2, Natália P Rocha2, Daniel Cisalpino3, David H Rodrigues2, Danielle G Souza3, Fabiana S Machado1,2, Milene A Rachid4, Antônio L Teixeira Jr1,2,5 and Alline C Campos1,2

Abstract

Background: Cerebral malaria (CM) is a clinical syndrome resulting from Plasmodium falciparum infection. A wide range of clinical manifestations follow the disease including cognitive dysfunction, seizures and coma. CM pathogenesis remains incompletely understood and without treatment this condition is invariably fatal. Artesunate has been accepted as the most effective drug for treating severe malaria. Besides its antiparasitic activity, an anti-inflammatory property has also been reported. In the current study, the immunomodulatory role of artesunate was investigated using a Plasmodium berghei ANKA model of CM, trough evaluation of behavioural changes and cytokines expression in hippocampus and in frontal cortex.

Methods: C57Bl/6 mice were infected with P. berghei by intraperitoneal route, using a standardized inoculation of 10⁶ parasitized erythrocytes. Memory function was evaluated using the step-down inhibitory avoidance test. The mRNA expression of IFN-γ, IL-1β, IL-6 and TNF in the frontal cortex and hippocampus of control and infected mice on day 5 post-infection were estimated by quantitative real time PCR. Plasmodium berghei -infected mice also received intraperitoneally a single dose of artesunate (32 mg/kg) on day 4 post-infection, and 24 hours after treatment behavioural and immunological analysis were performed. The protein levels of cytokines IL-2, IL-6, IL-10, IL-17, IFN-γ, TNF in the serum, frontal cortex and hippocampus of controls and P. berghei -infected mice treated or not treated with artesunate were determined using a cytometric bead array (CBA) kit. The survival and neurological symptoms of CM were also registered.

Results: CM mice presented a significant impairment of aversive memory compared to controls on day 5 post-infection. A higher mRNA expression of pro-inflammatory cytokines was found in the hippocampus and frontal cortex of infected mice. A single dose of artesunate was also able to decrease the expression of inflammatory cytokines in the hippocampus and frontal cortex of P. berghei-infected mice. In parallel, a significant improvement in neurological symptoms and survival were observed in artesunate treated mice.

Conclusions: In summary, the current study provided further evidence that CM affects key brain areas related to cognition process. In addition, different patterns of cytokine expression during the course of CM could be modulated by a single administration of the anti-malarial artesunate.

Keywords: Malaria, Cerebral malaria, Memory impairment, Artesunate, Cytokines, Neuroinflammation
Background
Cerebral malaria (CM) is a potentially reversible, diffuse encephalopathy characterized by the presence of asexual forms of *Plasmodium falciparum* parasites in the peripheral blood smears, and altered level of consciousness in the absence of other causes of encephalopathy, especially meningoencephalitis [1]. This condition accounts for approximately 80% of all fatal cases of malaria, being the leading cause of hospitalization and mortality of children under five years of age in sub-Saharan Africa [2,3]. A series of residual symptoms may follow the resolution of CM including cognitive, behavioural and motor changes [4]. Moreover, a significant social, economic and educational burden has been reported in endemic areas of malaria [5].

Although vascular, immunological and metabolic changes have been implicated in CM pathogenesis, it remains largely unknown [6]. The obstruction of cerebral microvasculature by sequestered infected red blood cells and an exacerbation in host inflammatory response are the two main non-exclusive theories widely accepted to explain this pathological process [7].

The release of pro-inflammatory mediators, including tumor necrosis factor (TNF) and interleukin (IL)-1, and immune cells infiltration in the brain parenchyma have been associated with cognitive and behavioural alterations during the acute phase of experimental CM [8-10]. However, it was only recently that a study conducted by Linares *et al.* [11] suggested that the immune response evoked by CM can specifically affect key brain areas involved in the control of cognition and mnemonic process, such as the hippocampus and the frontal cortex.

Without treatment CM invariably leads to death. Emergency management is based on the correction of metabolic states, re-establishment of vital physiological functions severely affected by CM and the administration of an effective anti-parasitic drug [12].

Artesunate, a semi-synthetic derivative of artemisinin, has been accepted as the most effective and safe drug for treating severe and chloroquine-resistant malaria [13]. Besides its antiparasitic activity, artesunate has shown to exhibit a putative anti-inflammatory profile in different inflammatory models, including sepsis, arthritis, systemic lupus erythematosus and allergic asthma [14-18]. Clemmer *et al.* [19] also demonstrated that artesunate was effective in rescuing mice in a late-stage CM and that artemether, another compound derivative of artemisinin, decreases leukocyte accumulation in brain vessels. However, no previous study has investigated the immunomodulatory properties of artesunate in the central nervous system (CNS) during the progression of CM.

The present study aimed to characterize the role of inflammatory mediated process within the hippocampus and frontal cortex in the behavioural changes (memory impairment and sickness behaviour) induced by CM. In addition, the putative immunomodulatory effect of a single dose of artesunate was also investigated in the experimental model of CM.

Methods
Ethics statement
This study was carried out in strict accordance with the Brazilian Government’s ethical and animal experiments regulations. The experimental protocol was approved by the Committee on the Ethics of Animal Experiments of the Universidade Federal de Minas Gerais (CETEA/UFGM, Permit Protocol Number 105/09). All tissue-collected procedures was performed under ketamine/xylazine anesthesia and all efforts were made to minimize animal suffering.

Animals
Female C57BL/6 mice (20-25 g), aged six to eight weeks, were obtained from Animal Care Facilities of the Institute of Biological Sciences, Federal University of Minas Gerais (ICB-UFGM), Belo Horizonte, Brazil. The animals were housed in groups of six mice per cage in a room controlled temperature (24°C) with food and water *ad libitum*. Experiments were performed on day 5 post-infection (pi), when mice infected with *Plasmodium berghei* strain ANKA develop brain inflammation without motor impairment.

Parasite, experimental infection and artesunate treatment
Due to the high degree of reproducibility, easily manageable characteristics and development of histopathological and neurological signs typical of human CM, the murine model using the *Plasmodium berghei* strain ANKA has been widely used to better understand this condition [20]. In the present study, blood stages of *P. berghei* strain ANKA constitutively expressing green fluorescent protein (*P. berghei* ANKA-GFP) (15c1 clone), kindly provided by Dr Claudio Marinho (Universidade de São Paulo), were stored in liquid nitrogen [19]. Mice were infected intraperitoneally (ip) with 10⁶ *P. berghei*-infected red blood cells suspended in 0.2 mL PBS [21]. Artesunate (Sigma, St. Louis, MO, USA) was dissolved in 5% sodium bicarbonate in saline and a single dose (32 mg/kg) was administered ip in the morning of the fourth day pi [19,22]. Control animals received the same volume of vehicle.

The percentage of parasitaemia was determined by flow cytometry. Briefly, a drop of blood from the tail was collected directly into 2 mL of PBS for flow cytometry analysis. Each sample was run on a FACScalibur (Becton Dickinson, San Jose, CA, USA) flow cytometer with a 488 nm argon laser and DIVA software (Becton Dickinson, San Jose, CA, USA). Erythrocytes were identified on the basis of their specific forward (FSC) and
side (SSC) light-scattering properties and a total of 100,000 events were counted for each sample. Mice were observed daily for parasitaemia, body weight, survival, and clinical neurological signs of CM (i.e., ataxia, paralysis and coma).

Step-down inhibitory avoidance test
The step-down inhibitory avoidance test was performed to assess short- and long-term aversive memory on day 5 and 6 post-infection (control and infected mice; n = 10 per group) as previously described by Reis et al. [23]. Briefly, in the training trial, animals were placed on the platform and their latency to step down on the grid with all four paws was measured. Immediately after the stepping down on the grid, the animals received a single mild foot shock (0.4 mA, 2.0 seconds). A retention test trial was performed 1.5 hour and 24 hours after the training section. The results were expressed as latency period to step down the platform, with a cut-off at 180 seconds. All tests were performed by the same investigator who was blinded to the animal status (control or infected).

Open field test
The open field test was performed as previously described by Barichello et al. [24] and conducted in order to evaluate the locomotor and exploratory activities on day 5 and 6 pi of control and infected mice (n = 5 per group). The apparatus is a 30 cm × 30 cm circular open field surrounded by 30 cm-high walls made of transparent plexiglass (Insight®, São Paulo, Brazil). The floor of the open field is divided in 12 rectangles by black lines. Briefly, animals were gently placed on the left rear quadrant, and then they were allowed to explore the arena for 5 minutes. The number of crossings (the number of times that animals crossed the black lines) and rearings (the exploration behaviour observed in rats subjected to a new environment) were recorded. Behavioural tests were performed by the same investigator who was blinded to the animal status (control or infected).

Rapid murine coma and behaviour scale (RMCBS)
Behavioural and functional parameters were evaluated using the RMCBS protocol as previously described by Carrol et al. [25]. The RMCBS is a quantitative and objective scale that enables an investigator to rapidly follow up the course of CM. The subjects were labelled as affected or not, and the levels of illness are correlated with neuropathological injury. This method intended to imitate the situation in the field and attempted to bring the animal model closer to the human disease [25].

The RMCBS consists of ten parameters (gait, balance, motor performance, body position, limb strength, touch sense, pinna reflex, toe pinch, aggression and grooming) based on the components of the SHIRPA (SmithKline/Harwell/Imperial College/Royal Hospital/Phenotype Assessment) score [26]. Each item is scored from zero as the lowest, to two as the highest, with a maximum total score of 20. The procedure was carried out on day 3 until day 5 pi. On day 5 pi the RMCBS were performed approximately 24 hours after artesunate treatment. A total of five animals per group were used. After the test all animals were sacrificed under deep anesthesia by ip injection of a mixture of Ketamine (150 mg/kg, Laboratório Cristália, Brazil) and Xylazine (10 mg/kg, Rompun®, Bayer, Germany), decapitated, frontal cortex and hippocampal dissected and serum collected for posterior cytokine expression assessment.

Hippocampal and frontal cortex mRNA expression of cytokines
The mRNA expression of IFN-γ, IL-1β, IL-6 and TNF in the hippocampus and frontal cortex of P. berghei-infected mice and matched controls (n = 5 per group) were estimated by quantitative real time PCR (polymerase chain reaction) at day 5 pi. RNA isolation was performed using Illustra RNAspin Mini RNA Isolation Kit (GE Healthcare, Little Chalfont, Buckinghamshire, UK). The RNA obtained was re-suspended in diethyl pyrocarbonate-treated water and stocked at -70°C until use. Reverse transcription was performed using 2 μg of total RNA, 200 U of reverse transcriptase, RT buffer 5 × (4 μl), 10 mM dNTPs (1 μl), RNAsin 10,000 U (0.2 μl) and oligo dT 15.50 μM (1.0 μl) in a final reaction volume of 20 μl. Resultant cDNA was used for qPCR. Real-time RT-PCR was performed on an ABI PRISM 7900 sequence-detection system (Applied Biosystems, CA, USA) by using SYBR Green PCR Master Mix (Applied Biosystems, CA, USA) after a reverse transcription reaction of 2 μg of total RNA by using M-MLV reverse transcriptase (Promega, Madison, Wisconsin-WI, USA). Specific primers were designed using Primer Express software and synthesized by integrated DNA technologies (IDT). The relative

Table 1 Oligonucleotide primers for real-time quantitative PCR (SYBR)

| Primer sequences | Forward | Reverse |
|------------------|---------|---------|
| IFN-γ | CAG CAG CCT TGT GAC | GGC AGA ATT AAG CTT |
| | CCT CTG AC | ATT GGG AC |
| TNF-α | ACG GCA TGG ATC TCA | AGA TAG CAA ATC GGC |
| | AAG AC | TGA CG |
| IL-1β | CTA CAG CGT CCG AGA | TCC ATT GAG GTG GAG |
| | TGA ACA AC | AGC TTT C |
| IL-6 | TTC CAT CCA GGT GCC TTC TTG | TTG GGA GTG GTA TCC |
| | TCA TCT GGA | TCT GTG A |
| 18S | CGT TCC ACC AAC TAA GGA CG | TTC AAC ACG GGA AAC |
| | CTC AC | CTC AC |
levels of gene expression were determined by the ΔΔCt Cycle threshold method as described by the manufacturer, in which data for each sample is normalized to 18S expression and data were shown as fold increase over the negative control (non-infected) group. Specific primers sequences are described in Table 1.

Cytometric bead array (CBA) and enzyme-linked immunosorbent assay (ELISA) analyses of cytokines

Hippocampal and frontal cortex tissues of controls (n = 5 per group) and *P. berghei*-infected mice treated or not treated (n = 5 per group) with a single dose of artesunate were carefully removed on day 5 pi and homogenized in a PBS-buffer extraction solution containing a protease-inhibitor cocktail. Lysates were centrifuged at 13,000 g for 10 minutes at 4°C and quantified using the Bradford assay reagent from Bio-Rad (Hercules, CA, USA). Analyses of serum and brain cytokine levels were determined using a mouse Th1/Th2/Th17 cytometric bead array kit (CBA; BD Biosciences, San Diego, CA, USA) and analysed on a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA). The following cytokines were measured:

![Graphs showing memory impairment and cytokine analysis](image)

**Figure 1** Short-term aversive memory impairment without locomotor and exploratory changes following *Plasmodium berghei* ANKA infection. Aversive memory, locomotor and exploratory activities measurement of *P. berghei*-infected mice on day 5 and 6 post-infection (pi) and of control group in the step-down inhibitory avoidance test (a-c) and in the open field (d-e). (a) Latency in seconds during training session (5 pi) in the step-down inhibitory avoidance test; (b) Short-term memory analysed 1.5 hours after training session in the step-down inhibitory avoidance test; (c) Long-term memory analysed 24 hours (6 pi) after training session in the step-down inhibitory avoidance test; (d) number of crossings and (e) number of rearing episodes analysed on day 5 post-infection in the open field. Results are expressed as mean ± SEM and are representative of two independent experiments. Asterisk(s) indicate statistical differences, *p < 0.05.
interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-17 (IL-17), Interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF). The concentration of the cytokine IL-1β was determined by ELISA (R&D Systems, Minneapolis, MN, USA) in accordance with manufacturer’s instructions.

Data analysis and statistical evaluation
Results obtained were presented as mean ± standard error of the mean (SEM). All data were tested for normality (Kolmorov-Smirnov’s test) and homogeneity of variances (Levene’s test). For variables normally distributed and with compliance of homogeneity of variances, differences were compared by using Student’s t-test, analysis of variance (ANOVA) or Two-way ANOVA. Duncan’s post-test was used as needed for multiple comparisons. In the case of variables not normally distributed, differences were analysed by Kruskal-Wallis non-parametric test. When significant effects were detected by this latter test, post-hoc comparisons were performed using the Mann-Whitney U test. Differences between lethality curves were calculated using the Log rank test. The significance level was set at the level of p < 0.05. Statistical analyses were performed using Prism 4 software (GraphPad, La Jolla, CA, USA) and SPSS software version 17.0 (SPSS Inc, Chicago, IL, USA).

Results
Plasmodium berghei-infected mice exhibited short-term aversive memory impairment
Figure 1 shows the effect of P. berghei infection in the step-down inhibitory avoidance test and open field test. No difference in the step-down latency between P. berghei-infected mice and controls was found in the training session (Figure 1a). In the test session performed 1.5 hours after the training to evaluate the short-term aversive memory, infected mice presented a significant decrease in the step-down latency (Figure 1b; p = 0.03). No difference was found in the long-term aversive memory analysed 24 hours (day 6 pi) after training session (Figure 1c; p = 0.99).

In the open field test, there were no significant differences in the number of crossings (Figure 1d; p = 0.89) and rearings (Figure 1e; p = 0.91) in the P. berghei-infected group compared to the controls on day 5 pi, indicating no difference in motor and exploratory activities, respectively. However, on day 6 pi, the period when the long-term memory was assessed, P. berghei-infected
Figure 3 (See legend on next page.)
mice presented significant deficits in motor (p = 0.001) and exploratory (p = 0.002) activities (data not shown).

Inflammatory changes in hippocampus and frontal cortex of *P. berghei*-infected mice, key areas related to memory and learning

In order to evaluate inflammatory parameters in specific regions well known to participate in memory formation and consolidation, the mRNA expression of IFN-$\gamma$, TNF, IL-1$\beta$, and IL-6 and the protein levels of IFN-$\gamma$, TNF, IL-1$\beta$, IL-2, IL-4, IL-6, IL-10 and IL-17 was analyzed in hippocampus and frontal cortex of controls and *P. berghei*-infected mice on day 5 pi.

The mRNA expression of TNF and IL-1$\beta$ was significantly increased in the frontal cortex and hippocampus of *P. berghei*-infected mice compared to controls. A higher mRNA expression of IFN-$\gamma$ and IL-6 was only observed in the hippocampus of *P. berghei*-infected mice (Figure 2).

Regarding protein levels, a significant increase of TNF, IL-1$\beta$ and IFN-$\gamma$ was found in the frontal cortex of infected animals, whereas a reduction of IL-10 was also observed (Figure 2). In the hippocampus higher levels of IL-1$\beta$, IL-6 and IFN-$\gamma$ were found on day 5 pi in parallel with a decrease in IL-2 expression (Figure 3). No significant differences were detected in the levels of IL-2, IL-4, IL-6 and IL-17 in the frontal cortex, and in the levels of IL-4, IL-10, IL-17 and TNF in the hippocampus when comparing controls and *P. berghei*-infected animals (Figures 3 and 4).

A single dose of artemesunate reduced cytokines levels in the hippocampus and frontal cortex of *P. berghei*-infected mice

The putative anti-inflammatory property of artemesunate has been demonstrated in different conditions [17,18]. To investigate its effects in CM, the cytokine levels in frontal cortex, hippocampus and serum of controls and *P. berghei*-infected mice that received or not a single dose of artemesunate were assessed.

*PbA*-infected mice presented an increase in frontal cortex levels of TNF ($F_{(2,12)} = 3.8; p < 0.05$), IFN-$\gamma$ ($F_{(2,12)} = 7.1; p < 0.01$) and IL-1$\beta$ ($F_{(2,12)} = 3.6; p < 0.05$), and decreased levels of IL-10 ($F_{(2,12)} = 3.1; p < 0.05$) in comparison with controls (Figure 3). The levels of cytokines of infected mice treated with artemesunate in the frontal cortex were similar to controls (Figure 3). *Plasmodium berghei*-infected mice showed an increase in hippocampal levels of IFN-$\gamma$ ($F_{(2,12)} = 7.7; p < 0.01$) and IL-6 ($F_{(2,12)} = 5.91; p < 0.05$), and decreased levels of IL-2 ($F_{(2,12)} = 8.6; p < 0.01$) in comparison with controls and treated *P. berghei*-infected mice (Figure 4). No significant difference was found in serum cytokine levels between treated and non-treated *P. berghei*-infected groups. When compared to the controls they exhibited higher serum levels of IL-6 ($\chi^2(df = 2, n = 15) = 9.5, p < 0.05$, control versus *P. berghei*, $U = 0; z = -2.6, p < 0.05$), IL-10 ($\chi^2(df = 2, n = 15) = 10.5, p < 0.05$, control versus *P. berghei*, $U = 0; z = -2.6, p < 0.05$), IFN-$\gamma$ ($\chi^2(df = 2, n = 15) = -10.8, p < 0.05$, control versus *P. berghei*, $U = 0; z = 2.6, p < 0.05$) and TNF ($\chi^2(df = 2, n = 15) = 10.8, p < 0.05$, control versus *P. berghei*, $U = 0; z = -2.6; p < 0.05$) than controls (Figure 5).

A single dose of artemesunate improved survival and clinical signs of cerebral malaria

*Plasmodium berghei*-infected mice treated with a single dose of artemesunate presented a significant improvement in survival ($\chi^2 = 8.5, p < 0.001$; Figure 6a) and a decrease in the percentage of parasitaemia on day 5 pi when compared with non-treated infected animals (Figure 6b). While *P. berghei*-infected mice presented significant changes in clinical parameters assessed by RMCBS, treated mice did not show clinical symptoms of CM (Figure 6c). Both treated and non-treated *P. berghei*-infected mice lost weight, but it was more significant in non-treated mice at day 5 pi (Figure 6d).

Discussion

In the present study, short-term aversive memory impairment was associated with increased levels of pro-inflammatory cytokines and decrease of regulatory mediators, such as IL-2 and IL-10, in the hippocampus and frontal cortex of *P. berghei*-infected mice. Therefore, different patterns of cytokines expression seem to be dependent on the region assessed, i.e., hippocampus or frontal cortex. This study investigated the expression (mRNA and protein) of cytokines in memory-related areas during CM, and the results reinforce a role for inflammation in the development and persistence of cognitive changes.

Inflammatory processes in the CNS, including an up-regulation of pro-inflammatory cytokines, have been associated with cognitive and behavioural dysfunctions in clinical and experimental CM. For instance, a previous study demonstrated that *P. berghei*-infected mice exhibit...
Figure 4 (See legend on next page.)
anxiety-like symptoms associated with increased brain levels of IL-1β and TNF, and histopathological changes in brainstem, cerebrum and hippocampus [10]. Desruisseaux et al. [8] found a significant impairment in working memory of PbA-infected mice, which was associated with cell infiltration and haemorrhage in thalamus, midbrain and cerebellum and with microglial activation in the cortex and hippocampus. Additionally, John et al. [27] have suggested a negative correlation between cognitive (attention and working memory) deficits and cerebrospinal fluid (CSF) levels of TNF in children with CM. Although these experimental and human studies have provided evidence for the role of altered levels of cytokines in cognitive and behavioural changes found in CM, few studies investigated the expression of cytokines in specific brain areas, such as hippocampus and frontal cortex, involved in these functions.

A recent study conducted by Linares et al. [11] demonstrated an increase in IFN-γ and TNF mRNA expression in several brain areas of *P. berghei*-infected mice, including cortex, hippocampus, thalamus/hypothalamus and brainstem. The upregulation of these cytokines was found in an early or asymptomatic stage of CM and was associated with an increased expression of immunoproteasome subunits. The replacement of proteasome subunits for immunoproteasome factors is a brain-inflammatory response that inhibits normal protein turnover [28]. There is evidence that proteasome also participates in neuronal survival and plasticity [29]. The substitution of proteasome for immunoproteasome complex could lead to neuronal death contributing to the cognitive deficits through impairment of synaptic function [28,30]. The present study provides evidence that pro-inflammatory cytokines expression remain upregulated in the hippocampus and frontal cortex until symptomatic stage of CM, culminating with cognitive impairment. It is worth mentioning that no impairment was found in long-term aversive memory, probably due to significant locomotor and exploratory deficits observed on day 6 pi. In agreement, previous studies have been demonstrated that changes in motor activity during CM occurred on day 6 p.i. whereas anxiety-like behaviour appeared earlier on day 5 pi [10,31]. Thus, it seems that behavioural disorders precede locomotor impairment during neuroinflammation caused by *P. berghei* ANKA infection.

CM is a clinical emergence that is invariably fatal without appropriate treatment [12]. Artesunate is a potent anti-malarial drug which has been widely accepted as the treatment of choice for severe malaria [13]. Apart from its well-known antiparasitic property, there is growing evidence suggesting an immunomodulatory activity of artesunate in infectious and autoimmune disorders [14-18]. Artesunate was able to protect mice subjected to sepsis by decreasing serum IL-6 and TNF levels via inhibition of Toll-like receptors expression and NF-κB activation in peritoneal macrophages [17,32,33]. In a rat model of arthritis, artesunate treatment significantly attenuated inflammation and cartilage damage by decreasing the levels of IL-1β, IL-17 and TNF in rat's hind paws. The anti-arthritic effect of artesunate was associated with NF-κB and mitogen-activated protein kinase signaling pathway suppression [18]. A decrease in cytokine levels and oxidative stress in lung tissue was also found in an allergic asthma model after artesunate treatment [14,15]. Altogether these studies provide strong evidence of artesunate capacity of modulating inflammatory response through the regulation of signaling pathways.

No previous study investigated the effect of artesunate in the CNS inflammation during CM. In the present study, a single dose of artesunate was able to decrease pro-inflammatory cytokines expression in the hippocampus and frontal cortex of *P. berghei*-infected mice in parallel with a significant reduction of parasitaemia and improvement in neurological symptoms and survival.

A single dose of artesunate was highly effective in clearing *P. berghei* parasitaemia at day 5 pi, rescuing mice in the late stages of CM. Reduction of the number of adherent leukocytes in brain vessels of *P. berghei*-infected mice was also observed 24 hours after a single dose of artemether [19]. These authors suggested that the decrease in brain inflammatory response could be a consequence of faster parasitaemia clearance associated with an intrinsic anti-inflammatory property presented by artemisinin derivatives [19]. Interestingly, a systemic release of pro-inflammatory cytokines during the acute phase of malaria is required for the control of parasitaemia [34]. Moreover, the serum levels of cytokines (IL-6, IFN-γ and TNF) in *P. berghei*-infected mice treated with artesunate were comparable to non-treated *P. berghei*-infected animals.

An *in vitro* study conducted by Lee et al. [35] showed that artesunate attenuates LPS-induced inflammatory responses in microglial BV2 cells by activating the Nrf2 transcription factor NF-E2-related factor-2 (Nrf2). This
Figure 5 (See legend on next page.)
transcription factor regulates inflammatory responsiveness in the CNS by mediating the expression of important antioxidant and phase II detoxification genes, and leading to an increase in the level of haem oxygenase-1 [35]. There is evidence that haem oxygenase-1 suppress the pathogenesis of experimental CM by preventing blood-brain barrier disruption, brain microvasculature congestion and neuro-inflammation [36,37]. The current study provided evidence of an anti-inflammatory role of artesunate in the CNS of *P. berghei*-infected mice indicating that CM symptoms prevention was not only due to parasitaemia clearance.

Experimental cerebral malaria development is dependent of Plasmodium strains and mice of susceptible genetic background. In systemic models of malaria, infected mice did not present CNS inflammation as well as CM signs but rather a significant increase in parasitemia and anemia. The lack of cognitive and neurological impairment after parasitemia clearance by chloroquine in those models supports a specific CNS involvement in CM outcome rather than severe systemic disease or the presence of the parasite per se [23]. A recent study conducted by Reis et al. [38] demonstrated that the statin Lovastatin (which exhibits a significant anti-inflammatory effect) was capable of decreasing pro-inflammatory cytokine levels in CNS during the acute phase of CM without influencing parasitaemia. However, improvement in survival rate was only observed in association with the antimalarial chloroquine. Despite being highly effective in preventing mortality, chloroquine alone did not prevent CM cognitive and behavioral outcome. This indicates that limiting the inflammatory damage to the brain is necessary to improve CM outcome in addition to an effective control of the parasitic disease. *P. berghei* ANKA mice were also treated with sodium diclofenac or allopurinol as control anti-inflammatory agents and did not detect protective effects in CM. In fact, sodium diclofenac increased mortality in infected animals, suggesting that anti-inflammatory drugs could trigger distinct immunomodulatory effects which could be effective or not to improve CM outcome [38].

**Conclusion**

In summary, the present study provided further evidence that key areas related to memory, such as hippocampus and frontal cortex, presented different patterns of cytokine expression. Furthermore, it seems that the anti-malarial artesunate presented not only a systemic antiparasitic activity but could also regulate inflammatory responses in the CNS by decreasing local pro-inflammatory cytokines release during the course of CM. As this study is largely

(See figure on previous page.)

**Figure 5** Cytokine levels in the serum of controls and infected mice following artesunate treatment. C57BL/6 mice were intraperitoneally infected with 10^6 parasitized erythrocytes and control (non-infected) animals received the same volume of PBS (n = 5 per group). On day 4 post-infection *P. berghei*-infected mice received a single dose of artesunate (ip 32 mg/kg). The serum was collected at day 5 post-infection and IFN-γ, TNF, IL-2, IL-4, IL-6, IL-10 and IL-17 levels were assessed by cytometric bead array (CBA). Results are expressed as mean ± SEM. Asterisk(s) indicate statistical differences. *p < 0.05.

**Figure 6** A single dose of artesunate improved survival and clinical signs of cerebral malaria. (a) Survival curve comparisons of *P. berghei*-infected mice treated or not treated with artesunate were expressed days after infection; (b) natural course of *P. berghei* infection was determined by flow cytometric analysis; (c) clinical signs of cerebral malaria assessed by the RMCBS scale; (d) weight variation in *P. berghei*-infected mice treated or not treated with artesunate. The data is representative of two independent experiments (n = 5 per group) and shown as the mean+/- SEM. Asterisk(s) indicate statistical differences, *p < 0.05.
descriptive, further studies are required to systematically investigate the immune/inflammatory pathways involved in the anti-inflammatory activity of artesunate in CM as well as its impact on cognitive outcome. Moreover, other symptoms typical of infection conditions such as fever should be also evaluated in association with parasitemia, body weight loss and clinical neurological signs of CM (ataxia, paralysis and coma) to determine the progression of the disease as well as to guide antimalarial treatment.

**Abbreviations**

CNS: Central nervous system; CM: Cerebral malaria; CBA: Cytometric bead array; ELISA: Enzyme-linked immunosorbent assay; IFN-γ: Interferon-γ; IL-1β: Interleukin-1 beta; IL-2: Interleukin-2; IL-6: Interleukin-6; IL-10: Interleukin-10; IL-17: Interleukin-17; RMBCS: Rapid murine coma and behaviour scale; SEM: Standard error of the mean; SHIRPA: Smithline/Harwell/Imperial College/Royal Hospital/Phenotype Assessment; TNF: Tumor necrosis factor; WHO: World health organization.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

ASM participated in the experimental design, carried out behavioural and immunological assays, data analysis and drafted the manuscript. FB participated in the experimental design, data analysis and carried out behavioural and immunological assays. NPR and DHR performed immunological assays. DC and DGS performed real time PCR analysis. FSM and MAR participated in the design and coordination of the study. ALT designed the study and was responsible for the interpretation of experiments and editing the manuscript. ACC participated in the experimental design and in the execution of experiments involving artesunate, immunological assays, data analysis and revised the manuscript. All authors have read and approved the final version of the manuscript.

**Acknowledgements**

This work was supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Rede Instituto Brasileiro de Neurociência (IBNet/FINEP), Brazil. We would like to thank Dr Leonardo Carvalho for providing artesunate.

**Author details**

1Programme in Health Sciences: Infectious Diseases and Tropical Medicine, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
2Laboratório de Imunofarmacologia, Department of Biochemistry and Immunology, Institute of Biological Sciences, Federal University of Minas Gerais, Av. Antônio Carlos, 6627, Pampulha, Belo Horizonte 31270-901, Brazil.
3Department of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
4Laboratory of Medical Investigation, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.

**Received:** 18 August 2013 **Accepted:** 29 October 2013 **Published:** 2 November 2013

**References**

1. Severa falciparum malaria. World health organization. Communicable diseases cluster. Trans R Soc Trop Med Hyg 2000, 94 Suppl 1:51–590.
2. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI: The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005, 434:214–217.
3. Gentilvoglio M, Mariotti R, Bertiet GC: Neuroinflammation and brain infections: historical context and current perspectives. Brain Res Rev 2011, 66:152–173.
4. Idro R, Jenkins NE, Newton CR: Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol 2005, 4:827–840.
5. Fernando SD, Rodrigo C, Rajapakse S: The ‘hidden’ burden of malaria: clinical immune suppression following infection. Malar J 2010, 9:366.
6. Hunt NH, Golenser J, Chan-Ling T, Parekh S, Rae C, Potter S, Merdana IM, Miu J, Ball HI: Immunopathogenesis of cerebral malaria. Int J Parasitol 2006, 36:569–582.
7. van der Heyde HC, Nolan J, Combes V, Gramaglia I, Grau GE: A unified hypothesis for the genesis of cerebral malaria: sequestration, inflammation and hemostasis leading to microcirculatory dysfunction. Trends Parasitol 2006, 22:503–508.
8. Desruisseaux MS, Gulinello M, Smith DN, Lee SC, Tsuj M, Weiss LM, Spray DC, Tanowitz HB: Cognitive dysfunction in mice infected with Plasmodium berghei strain ANKA. J Infect Dis 2008, 197:1621–1627.
9. Lackner P, Beer R, Heusler V, Goebel G, Ruddick D, Helbok R, Tannich E, Schmutzhard E: Behavioural and histopathological alterations in mice with cerebral malaria. Neuropathol Appl Neurobiol 2006, 32:177–188.
10. de Miranda AS, Lacerda-Queiroz N, de Carvalho Vieira M, Rodrigues DH, Rachid MA, Queiroz J, Teixeira AL: Anxiety-like behavior and proinflammatory cytokine levels in the brain of C57BL/6 mice infected with Plasmodium berghei (strain ANKA). Neurosci Lett 2011, 491:202–206.
11. Linares M, Martin-Garcia P, Perez-Benavente S, Sanchez-Noguerol J, Puyet A, Bautista JM, Diez A: Brain-derived neurotrophic factor and the course of experimental cerebral malaria. Brain Res 2013, 1490:210–224.
12. Mithra SK, Newton CR: Diagnosis and management of the neurological complications of falciparum malaria. Nat Rev Neurol 2009, 5:189–198.
13. Rosenthal PJ: Artesunate for the treatment of severe falciparum malaria. N Engl J Med 2008, 358:1829–1836.
14. Cheng C, Ho WE, Goh PJ, Guan SP, Kong LR, Lai WQ, Leung BP, Wong WS: Anti-malarial drug artemisinates attenuates experimental allergic asthma via inhibition of the phosphoinositide 3-kinase/Akt pathway. PLoS One 2011, 6:e20932.
15. Ho WE, Cheng C, Peh HY, Xu F, Tannenbaum SR, Ong CN, Wong WS: Anti-malarial drug artemisinates ameliorates oxidative lung damage in experimental allergic asthma. Free Radic Biol Med 2012, 53:498–507.
16. Jin Q, Zhang H, Gu Z, Zhao S, Xu T, Zhou K, Jiang B, Wang J, Zeng X, Sun L: A pilot study of the therapeutic efficacy and mechanism of artesunate in the MRL/lpr murine model of systemic lupus erythematosus. Cell Mol Immunol 2009, 6:461–467.
17. Li B, Li J, Pan X, Ding G, Cao H, Jiang W, Zheng J, Zhou H: Artesunate protects sepsis model mice challenged with Staphylococcus aureus by decreasing TNF-alpha release via inhibition TLR2 and Nod2 mRNA expressions and transcription factor NF-kappaB activation. Int Immunopharmacol 2010, 10:344–350.
18. Li Y, Wang S, Wang Y, Zhou C, Chen G, Shen W, Li C, Lin W, Lin S, Huang H, Liu P, Shen X: Inhibitory effect of the anti-malarial agent artemoside on collagen-induced arthritis in rats through nuclear factor kappa B and mitogen-activated protein kinase signaling pathway. Trans Res 2013, 161:89–98.
19. Clemmer L, Martins YC, Zanini GM, Frangos JA, Carvalho LJ: Artemether and artesunate show the highest efficacies in rescuing mice with late-stage cerebral malaria and rapidly decrease leukocyte accumulation in the brain. Antimicrob Agents Chemother 2011, 55:1383–1390.
20. Lou J: Pathogenesis of cerebral malaria: recent experimental data and possible applications for humans. Clin Microbiol Rev 2001, 14:810–820.
21. Grau GE, Piquet PF, Engers HD, Louis JA, Vassali P, Lambeth JP: L3T4+ T lymphocytes play a major role in the pathogenesis of murine cerebral malaria. J Immunol 1986, 137:2348–2354.
22. Martins YC, Clemmer L, Orjuela-Sanchez P, Zanini GM, Ong PK, Frangos JA, Carvalho LJ: Slow and continuous delivery of a low dose of nimodipine improves survival and electrocardiogram parameters in rescue therapy of mice with cerebral malaria. Malar J 2013, 12:138.
23. Reis PA, Corim CM, Hermani F, Silva B, Barichello T, Portella AC, Gomes FC, Liu P, Frutuoso VS, Oliveira MF: Antimalarial drug artesunate ameliorates oxidative lung damage in the MRL/lpr murine model of systemic lupus erythematosus. Cell Mol Immunol 2009, 6:461–467.
24. Barichello T, Dos Santos I, Savi GD, Simoes LR, Generoso JS, Corim CM, Sachs D, Tewes AE, Quevedo J: Depressive-like behavior and proinflammatory interleukine levels in the brain of rats submitted to pneumococcal meningitis. Brain Res Bull 2010, 82:243–246.
25. Carroll RW, Wainwright MS, Kim KY, Kibadi T, Gomez ND, Taylor T, Haldar K: A rapid murine coma and behavior scale for quantitative assessment of murine cerebral malaria. PLoS One 2010, 5:e13124. doi:10.1371/journal.pone.0013124.
26. Rogers DC, Fisher EM, Brown SD, Peters J, Hunter AJ, Martin JE: Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm Genome 1997, 8:711–713.

27. John CC, Panoskaltsis-Mortari A, Opoka RO, Park GS, Orchard PJ, Jurek AM, Ido R, Byarugaba J, Soivin MI: Cerebrospinal fluid cytokine levels and cognitive impairment in cerebral malaria. Am J Trop Med Hyg 2008, 78:198–205.

28. Nguyen TP, Soukup VM, Gelman BB: Persistent hijacking of brain proteasomes in HIV-associated dementia. Am J Pathol 2010, 176:893–902.

29. Dong C, Upadhyya SC, Ding L, Smith TK, Hegde AN: Proteasome inhibition enhances the induction and impairs the maintenance of late-phase long-term potentiation. Learn Mem 2008, 15:335–347.

30. Bิง gol B, Sheng M: Deconstruction for reconstruction: the role of proteolysis in neural plasticity and disease. Neuron 2011, 69:22–32.

31. Lacerda-Queiroz N, Rodrigues DH, Vilela MC, Miranda AS, Amaral DC, Camargo ER, Carvalho L, Howe CL, Teixeira MM, Teixeira AL: Inflammatory changes in the central nervous system are associated with behavioral impairment in Plasmodium berghei (strain ANKA)-infected mice. Exp Parasitol 2010, 125:271–278.

32. Jiang W, Li B, Zheng X, Liu X, Cen Y, Li J, Pan X, Cao H, Zheng J, Zhou H: Artesunate in combination with oxacillin protect sepsis model mice challenged with lethal live methicillin-resistant Staphylococcus aureus (MRSA) via its inhibition on proinflammatory cytokines release and enhancement on antibacterial activity of oxacillin. Int Immunopharmacol 2011, 11:1065–1073.

33. Li B, Zhang R, Li J, Zhang L, Ding G, Luo P, He S, Dong Y, Jiang W, Lu Y, Cao H, Zheng J, Zhou H: Antimalarial artesunate protects sepsis model mice against heat-killed Escherichia coli challenge by decreasing TLR4, TLR9 mRNA expressions and transcription factor NF-kappa B activation. Int Immunopharmacol 2008, 8:379–389.

34. Bakir HY, Tomiyama C, Abo T: Cytokine profile of murine malaria: stage-related production of inflammatory and anti-inflammatory cytokines. Biomed Res 2011, 32:203–208.

35. Lee IS, Ryu DK, Lim J, Cho S, Kang BY, Choi HJ: Artesunate activates Nrf2 pathway-driven anti-inflammatory potential through ERK signaling in microglial BV2 cells. Neurosci Lett 2012, 509:17–21.

36. Pamplona A, Ferreira A, Balla J, Jeney V, Chora A, Rodrigues CD, Gregoire IP, Cunha-Rodrigues M, Portugal S, Soares MP, Mota MM: Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nat Med 2007, 13:703–710.

37. Pena AC, Penacho N, Mancio-Silva L, Neres R, Seixas JD, Fernandes AC, Romao C, Mota MM, Bernardes GJ, Pamplona A: A novel carbon monoxide-releasing molecule fully protects mice from severe malaria. Antimicrob Agents Chemother 2012, 56:1281–1290.

38. Reis PA, Estato V, da Silva TL, d’Avila JC, Siqueira LD, Assis EF, Bozza PT, Bozza FA, Tibirica EV, Zimmerman GA, Castro-Faria-Neto HC: Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria. PLoS Pathog 2012, 8:e1003099.

doi:10.1186/1475-2875-12-388
Cite this article as: Miranda et al.: Further evidence for an anti-inflammatory role of artesunate in experimental cerebral malaria. Malaria Journal 2013 12:388.